The U.S. Tennis Association (USTA) is urging tennis players who will compete at the 2017 U.S. Open to get vaccinated for whooping cough. The Vaccines for the Prevention of Whooping Cough (VPW) vaccine is recommended for all players, except children over the age of 6 months, who will attend events in the United States. Under the USTA’s recommendations, players will receive the vaccine at a clinic at USTA Billie Jean King National Tennis Center on May 7, an event also open to the public.
Vice President of Tennis and Tournament Operations Steve Simon said: “This vaccine is considered a particularly safe and effective way to protect against whooping cough, which in rare cases can lead to serious consequences, such as severe pneumonia or pneumonia that can lead to permanent lung damage.”
“For tennis players who are younger than 15, I encourage them to take the vaccination seriously,” Simon said. “The best way to protect against whooping cough is to immunize yourself against it.”
There are 55 major events in the world of professional tennis during the 2017-2018 season, with two more at the end of August. The Vaccines for the Prevention of Whooping Cough vaccine was originally developed by the World Health Organization (WHO) in the 1970s and is now recommended by the WHO as part of childhood vaccinations for whooping cough, which causes the extreme coughs in tennis players. The WHO recommended the vaccine two years ago, after a bout of whooping cough that claimed the lives of 12 infants worldwide, including one child in Denmark and six in Switzerland. The death was the first since 2013.